Fear keeping some cancer patients from COVID-19 vaccination
December 9, 2021
Of the patients surveyed, 56% reported receiving at least one dose of a COVID-19 vaccination, which is lower than the community vaccination rate of 76%.
December 9, 2021
Of the patients surveyed, 56% reported receiving at least one dose of a COVID-19 vaccination, which is lower than the community vaccination rate of 76%.
December 9, 2021
A newly published paper provides a long-sought link between environmental exposures and conditions like Gulf War syndrome, breast implant illness, chemical intolerance and possibly even long-haul COVID-19. This discovery represents a major step toward improved diagnosis, treatment and prevention.
December 9, 2021
Dr. Marjorie David, director of the Molecular Diagnostic Laboratory of the Department of Pathology and Laboratory Medicine, and her team’s efforts were featured by KSAT 12. The UT Health San Antonio Molecular Diagnostic Laboratory, GCCRI Genome Sequencing Facility and GCCRI Bioinformatics Team are involved in SARS-CoV-2 variant identification efforts for Bexar County. Watch story
December 9, 2021
Dr. Marjorie David, director of the Molecular Diagnostic Laboratory of the Department of Pathology and Laboratory Medicine, and Dr. Jason Bowling, Infectious Diseases, were featured in a San Antonio Express-News front-page story on the lab’s leading efforts to sequence coronavirus samples for variants, including omicron. Read story
December 8, 2021
Dr. Kate Lathrop and Dr. Sukeshi Arora, Medicine/Hematology-Oncology and Mays Cancer Center, were interviewed for this News 4 story, shared by CBS Austin, about a survey conducted by the Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, in collaboration with clinical partner University Health, that shows high-risk cancer patients are […]
December 8, 2021
This story is about a survey conducted by the Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, in collaboration with clinical partner University Health, that shows high-risk cancer patients are choosing to get the COVID-19 vaccine at significantly lower levels than the general population. Read story